These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND FUBP1, FBP, 8880, ENSG00000162613, FUBP AND Prognosis
13 results:

  • 1. Genomic alterations of oligodendrogliomas at distant recurrence.
    Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
    Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
    Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
    Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
    Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
    Front Immunol; 2022; 13():998236. PubMed ID: 36110851
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
    Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
    Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
    Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
    Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
    Tanboon J; Williams EA; Louis DN
    J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. TCF12 is mutated in anaplastic oligodendroglioma.
    Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
    Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.
    Sahebjam S; McNamara MG; Mason WP
    CNS Oncol; 2013 Jul; 2(4):351-8. PubMed ID: 25054579
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Loss of CIC and fubp1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
    Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
    Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Frequent ATRX, CIC, fubp1 and IDH1 mutations refine the classification of malignant gliomas.
    Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
    Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.